Trial document




This trial has been registered retrospectively.
drksid header

  DRKS00015823

Trial Description

start of 1:1-Block title

Title

Development and piloting of a decision support tool to support decision making in the context of risk-adapted prevention for patients with pathogenic BRCA1/2 mutations

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

not available

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

http://none

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Creation of a patient-oriented decision aid based on a genetic test for the probability of breast cancer.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

-Supporting the decision-making process and minimising decision-making conflicts within the framework of risk-adapted prevention.
-Supporting those seeking advice in actively including their preferences and values in decision-making.
-Improving knowledge and understanding of the individual risk of disease and the benefits and risks of different prevention strategies.
-Through decision-making participation, a reduction of emotional stress and personal maturation is aimed at.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00015823
  •   2019/06/14
  •   [---]*
  •   yes
  •   Approved
  •   17-128, Ethik-Kommission der Medizinischen Fakultät der Universität zu Köln
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   C50 -  Malignant neoplasm of breast
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Patients with BRCA1/2 (BReast CAncer) mutation without cancer

    (Patients receive a written decision guide; at the end of their decision-making process, patients complete a standardized questionnaire to see how helpful the written decision guide has been.)
  •   Patients with BRCA1/2 mutation with cancer
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Open (masking not used)
  •   [---]*
  •   Other
  •   Prevention
  •   Parallel
  •   N/A
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Change in the severity of the decision conflict (DCS-D score difference) between the time points T1 (after genetic reporting/risk consultation at the doctor's consultation) and T2 (after decision for an alternative course of action has been made)

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

Comparison with patients from other clinics without decision aids

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2018/11/15
  •   278
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Female
  •   18   Years
  •   80   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

1. healthy women
2. women with unilateral breast cancer (first disease without metastasis)
3. sufficient decision-making ability to give informed written consent in accordance with the ICH-GCP guidelines and national/local regulations.
4. sufficient language skills to complete the questionnaires

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

1. women with relapse or metastasis of breast cancer, ovarian cancer, or other cancer who are ill
2. women unable to give informed consent
3. women without sufficient knowledge of the German language

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Universitätsklinikum Köln
    • Kerpener Str. 62
    • 50924  Köln
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Institut für Gesundheitsökonomie und Klinische Epidemiologie
    • Ms.  Dr.  Sibylle  Kautz-Freimuth 
    • Gleueler Straße 176-178
    • 50935  Köln
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinikum Köln
    • Ms.  Prof. Dr.  Rita  Schmutzler 
    • Kerperner Straße 34
    • 50931  Köln
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Landeszentrum Gesundheit Nordrhein-Westfalen (LZG.NRW)
    • Gesundheitscampus 10
    • 44801  Bochum
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.